Lannett gets FDA OK for generic of Levaquin

Lannett announced that it received approval from the FDA of its abbreviated new drug application, or ANDA, for Levofloxacin oral solution USP, 25 mg/mL, the therapeutic equivalent to the reference listed drug, Levaquin oral solution, 25 mg/mL, of Janssen Pharmaceuticals. For the 12 months ended April 2018, total U.S. sales of Levofloxacin oral solution USP, 25 mg/mL, was approximately $6M, according to IMS.

https://bit.ly/2J1UMmJ